Atrion (NASDAQ:ATRI) Announces Quarterly Earnings Results

Atrion (NASDAQ:ATRIGet Free Report) announced its quarterly earnings data on Friday. The medical instruments supplier reported $1.59 earnings per share (EPS) for the quarter, reports. Atrion had a net margin of 11.46% and a return on equity of 8.07%. The company had revenue of $47.33 million during the quarter.

Atrion Price Performance

Atrion stock opened at $445.35 on Monday. The firm has a market capitalization of $783.82 million, a P/E ratio of 41.86 and a beta of 0.62. The stock has a fifty day moving average price of $419.70 and a two-hundred day moving average price of $368.60. Atrion has a 52-week low of $274.98 and a 52-week high of $602.59.

Atrion Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 29th. Investors of record on Friday, March 15th were paid a $2.20 dividend. This represents a $8.80 annualized dividend and a yield of 1.98%. The ex-dividend date of this dividend was Thursday, March 14th. Atrion’s dividend payout ratio is 82.71%.

Analyst Ratings Changes

Separately, StockNews.com lowered shares of Atrion from a “hold” rating to a “sell” rating in a research report on Wednesday, May 1st.

Check Out Our Latest Research Report on ATRI

Institutional Investors Weigh In On Atrion

Large investors have recently made changes to their positions in the company. Copeland Capital Management LLC boosted its position in Atrion by 56.4% in the fourth quarter. Copeland Capital Management LLC now owns 86 shares of the medical instruments supplier’s stock valued at $33,000 after buying an additional 31 shares in the last quarter. Quadrant Capital Group LLC bought a new position in shares of Atrion in the fourth quarter valued at approximately $36,000. Harbor Investment Advisory LLC boosted its holdings in shares of Atrion by 33.1% in the 4th quarter. Harbor Investment Advisory LLC now owns 189 shares of the medical instruments supplier’s stock worth $72,000 after acquiring an additional 47 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Atrion by 592.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 270 shares of the medical instruments supplier’s stock worth $102,000 after acquiring an additional 231 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in Atrion during the 4th quarter worth approximately $108,000. Institutional investors own 66.19% of the company’s stock.

Atrion Company Profile

(Get Free Report)

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.

Further Reading

Earnings History for Atrion (NASDAQ:ATRI)

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.